Hepatitis C Screening Paired With Mammography

Context :

Organized breast cancer screening has been introduced in France since 2004. It concerns women aged 50 to 74 years old with average risk (no symptoms and no risk factors). This systematic screening reaches approximately 70% of the includable women. At the same time, it is estimated that 10 to 15% of women aged 50 to 74 undergo screening as part of an individual detection process.

The seroprevalence of hepatitis C in the general French population is less than 1%, but it is estimated that around 75,000 people living with the virus are unaware of their seropositivity. Among them, the risk of a late diagnosis is the risk of cirrhosis or hepatocellular carcinoma. Screening for hepatitis C is also justified now that the new treatments is universally accessible with a remarkable efficacy (>95%). These pan-genotypic treatments are of short duration and have very few adverse effects.

The WHO has set a goal of eliminating hepatitis by 2030 and France has gone a step further and proposed an elimination date of 2025. These objectives are not achievable without improved screening, the cornerstone of access to treatment. The objective is therefore to propose targeted screening in certain sub-population to organize micro elimination phenomena. Women over 50 years of age constitute a sub population at risk.

Objectives :

The objective of the study is to evaluate the adherence rate of women aged 50 to 74 years to hepatitis C screening by TROD paired with systematic breast cancer screening.

The secondary objectives of the study are, among women aged 50-74 presenting for breast cancer screening in the city of Montpellier, to estimate:

• The prevalence of viral hepatitis C
• The prevalence of chronic viral hepatitis C
• The retrospective care cascade of hepatitis C in women screened positive for chronic hepatitis C
• Access to hepatitis C care among positive for chronic hepatitis C

Methodology:

Type of study: Prospective screening procedure evaluation study.

Primary endpoint:

• The number of women who agreed to undergo the HCV test among those who were offered the test will be calculated = adherence to the proposed screening.

Secondary endpoints:

• Number of hepatitis C positive TRODs compared to the number of TRODs performed
• Number of HCV RNA positives among the number of hepatitis C positive TRODs.
• Retrospective chronic viral hepatitis C care cascade for participants with a positive TROD
• Access to care and prospective cascade of care

Statistical analysis:

The main analyses will be descriptive. The main characteristics of the participants will be described by the mean/standard deviation or median/interquartile range when the variable is quantitative and by a proportion with confidence interval when the variable is qualitative.

The judgment criteria will be described by percentages with their 95% confidence intervals. The fibrosis score will be presented in classes.

Inclusion criteria

• - Women aged 50-74 inclusive
• Doing a breast cancer screening
• Able to understand and complete a questionnaire on their own or with the help of a third party
• Able to understand the study and follow the protocol
• Having signed the consent form
• With social security plan

Exclusion criteria

• - Cannot sign the consent or follow the protocol
• Under French legal protection measure (sauvegarde de justice, tutelle or curatelle)